These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 9972671)
21. Borderline hyperprolactinemia in infertile women: evaluation of the prolactin response to thyrotropin releasing hormone and double-blind placebo-controlled treatment with bromocriptine. Glazener CM; Kelly NJ; Hull MG Gynecol Endocrinol; 1987 Dec; 1(4):373-8. PubMed ID: 3140587 [TBL] [Abstract][Full Text] [Related]
22. Hachimijiogan treatment is effective in the management of infertile women with hyperprolactinemia or bromocriptine-resistant hyperprolactinemia. Usuki S; Usuki Y Am J Chin Med; 1989; 17(3-4):225-41. PubMed ID: 2633624 [TBL] [Abstract][Full Text] [Related]
23. Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Saucedo R; Rico G; Basurto L; Ochoa R; Zárate A Gynecol Obstet Invest; 2002; 53(2):114-7. PubMed ID: 11961386 [TBL] [Abstract][Full Text] [Related]
24. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052 [TBL] [Abstract][Full Text] [Related]
25. [An endocrinological study of hyperprolactinemia and its treatment (author's transl)]. Kimura T; Narita O; Suzuki M; Tomoda Y; Kuwayama A; Kageyama N Nihon Sanka Fujinka Gakkai Zasshi; 1980 Jun; 32(6):784-92. PubMed ID: 6787150 [TBL] [Abstract][Full Text] [Related]
26. Clinical and hormonal response to short-term intermittent versus continuous oral bromocriptine in hyperprolactinemic women. Parra A; Crespo G; Coria I; Espinosa de los Monteros A Int J Fertil Menopausal Stud; 1995; 40(2):96-101. PubMed ID: 7599666 [TBL] [Abstract][Full Text] [Related]
31. [Influence of the presence of hot flashes during menopause on the metabolism of nitric oxide. Effects of hormonal replacement treatment]. Leal Hernández M; Abellán Alemán J; Carbonell Meseguer LF; Díaz Fernández J; García Sánchez FA; Martínez Selva JM Med Clin (Barc); 2000 Jan; 114(2):41-5. PubMed ID: 10702946 [TBL] [Abstract][Full Text] [Related]
32. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas. Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075 [TBL] [Abstract][Full Text] [Related]
34. Hyperprolactinemia in oligospermic Nigerian males: effect of bromocriptine treatment. Modebe O Int J Fertil Menopausal Stud; 1994; 39(2):95-9. PubMed ID: 8012447 [TBL] [Abstract][Full Text] [Related]
35. Subnormal prolactin responsiveness to thyrotropin-releasing hormone (TRH) in women with primary empty sella syndrome. Celani MF; Giambuzzi G; Simoni M; Montanini V J Endocrinol Invest; 1987 Aug; 10(4):421-5. PubMed ID: 3119699 [TBL] [Abstract][Full Text] [Related]
36. [Bromocriptine treatment of hyperprolactinemia]. Gauer J; Heberling HJ; Stubert B; Richardt W; Lohmann D Z Gesamte Inn Med; 1985 Jul; 40(13):393-6. PubMed ID: 4036221 [TBL] [Abstract][Full Text] [Related]